Bolt Biotherapeutics, Inc. (BOLT) Stock

Bolt Biotherapeutics, Inc., headquartered in Redwood City, California, is a dynamic clinical-stage biotechnology company focused on advancing innovative immuno-oncology agents. Established in 2015 as Bolt Therapeutics, Inc., the company rebranded to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics is dedicated to developing therapies that harness the immune system to target and eliminate tumor cells, addressing critical unmet needs in oncology.

Central to Bolt Biotherapeutics' pipeline is BDC-1001, a promising human epidermal growth factor receptor 2 (HER2) targeting agent currently in Phase I/II clinical trials. This therapy is designed for patients with HER2-expressing solid tumors, including those with HER2-low expression levels. Additionally, the company is advancing BDC-2034, a carcinoembryonic antigen (CEA) program aimed at colorectal, non-small cell lung, pancreatic, and breast cancers. Moreover, Bolt Biotherapeutics is developing BDC-3042, an agonist antibody program targeting Dectin-2 receptors on macrophages within the tumor microenvironment to facilitate immune cell repolarization.

Innovatively, Bolt Biotherapeutics is also exploring a programmed cell death-ligand 1 (PD-L1) programm tailored for tumors resistant to traditional immune checkpoint inhibitors. With a robust commitment to pioneering immunotherapy solutions, Bolt Biotherapeutics continues to push the boundaries of cancer treatment, striving to improve outcomes and quality of life for patients worldwide.